News - KDR amplification

11ms

Druggable genomic landscapes of high-grade gliomas. (PubMed, Front Med (Lausanne))

Among the JH MTB cohort of patients with IDH1 wild-type high-grade gliomas who received targeted therapies, trametinib monotherapy or in combination with dabrafenib conferred radiographic partial response in 75% of patients harboring BRAF or NF1 actionable mutations...While multiple host, tumor and drug-related features may limit the delivery and efficacy of targeted therapies for patients with high-grade gliomas, genotype-matched targeted therapies confer favorable clinical outcomes. Further studies are needed to generate more data on the impact of biochemical features of targeted therapies on their clinical efficacy for high-grade gliomas.

11 months ago

Journal

BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • KDR (Kinase insert domain receptor)

BRAF mutation • NF1 mutation • IDH wild-type • KDR amplification • KDR amplification

Mekinist (trametinib) • Tafinlar (dabrafenib) • Cabometyx (cabozantinib tablet)

over1year

Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. (PubMed, J Pathol)

In summary, a significant proportion of HAS in Taiwan is associated with ESRD and harbors a distinctive mutational signature, which concomitantly links nephrotoxicity and mutagenesis resulting from the exposure to aristolochic acid or related compounds. High TMB may support the eligibility for immunotherapy in treating ESRD-associated HAS.

over 1 year ago

Journal • Tumor mutational burden • IO biomarker

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KDR (Kinase insert domain receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)

TMB-H • CDKN2A deletion • ATRX mutation • KDR mutation • KDR amplification • KDR amplification

over3years

The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma. (PubMed, Neurooncol Adv)

Meanwhile, 4q12 amplification (KDR/PDGFRA/KIT) denoted patients with worse OS. Identifying subgroups of GBM IDH-WT with distinct survival is important for optimal clinical trial design, incorporation of targeted therapies, and personalized neuro-oncological care.

over 3 years ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • KDR (Kinase insert domain receptor) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

TP53 mutation • EGFR mutation • RB1 mutation • SETD2 mutation • KDR amplification • KDR amplification

MSK-IMPACT